Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan | Zendy

Rasmus Juul Kildemoes | Zendy; Michael Højby Rasmussen | Zendy; Henrik Agersø | Zendy; Rune Viig Overgaard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

Author(s) -

Rasmus Juul Kildemoes,

Michael Højby Rasmussen,

Henrik Agersø,

Rune Viig Overgaard

Publication year - 2020

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgaa775

Subject(s) - context (archaeology) , standard deviation , medicine , dosing , insulin like growth factor , pharmacodynamics , growth hormone deficiency , pharmacokinetics , growth hormone , endocrinology , mathematics , hormone , statistics , growth factor , biology , paleontology , receptor

Somapacitan is a long-acting growth hormone (GH) in development for once-weekly treatment of GH deficiency (GHD). Optimal monitoring of insulin-like growth factor-I (IGF-I) levels must account for weekly IGF-I fluctuations following somapacitan administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research